Abstract:Background: The rising global cancer burden has led to an increasing demand for imaging tests such as [18F]fluorodeoxyglucose ([18F]FDG)-PET-CT. To aid imaging specialists in dealing with high scan volumes, we aimed to train a deep learning artificial intelligence algorithm to classify [18F]FDG-PET-CT scans of patients with lymphoma with or without hypermetabolic tumour sites. Methods: In this retrospective analysis we collected 16 583 [18F]FDG-PET-CTs of 5072 patients with lymphoma who had undergone PET-CT before or after treatment at the Memorial Sloa Kettering Cancer Center, New York, NY, USA. Using maximum intensity projection (MIP), three dimensional (3D) PET, and 3D CT data, our ResNet34-based deep learning model (Lymphoma Artificial Reader System [LARS]) for [18F]FDG-PET-CT binary classification (Deauville 1-3 vs 4-5), was trained on 80% of the dataset, and tested on 20% of this dataset. For external testing, 1000 [18F]FDG-PET-CTs were obtained from a second centre (Medical University of Vienna, Vienna, Austria). Seven model variants were evaluated, including MIP-based LARS-avg (optimised for accuracy) and LARS-max (optimised for sensitivity), and 3D PET-CT-based LARS-ptct. Following expert curation, areas under the curve (AUCs), accuracies, sensitivities, and specificities were calculated. Findings: In the internal test cohort (3325 PET-CTs, 1012 patients), LARS-avg achieved an AUC of 0·949 (95% CI 0·942-0·956), accuracy of 0·890 (0·879-0·901), sensitivity of 0·868 (0·851-0·885), and specificity of 0·913 (0·899-0·925); LARS-max achieved an AUC of 0·949 (0·942-0·956), accuracy of 0·868 (0·858-0·879), sensitivity of 0·909 (0·896-0·924), and specificity of 0·826 (0·808-0·843); and LARS-ptct achieved an AUC of 0·939 (0·930-0·948), accuracy of 0·875 (0·864-0·887), sensitivity of 0·836 (0·817-0·855), and specificity of 0·915 (0·901-0·927). In the external test cohort (1000 PET-CTs, 503 patients), LARS-avg achieved an AUC of 0·953 (0·938-0·966), accuracy of 0·907 (0·888-0·925), sensitivity of 0·874 (0·843-0·904), and specificity of 0·949 (0·921-0·960); LARS-max achieved an AUC of 0·952 (0·937-0·965), accuracy of 0·898 (0·878-0·916), sensitivity of 0·899 (0·871-0·926), and specificity of 0·897 (0·871-0·922); and LARS-ptct achieved an AUC of 0·932 (0·915-0·948), accuracy of 0·870 (0·850-0·891), sensitivity of 0·827 (0·793-0·863), and specificity of 0·913 (0·889-0·937). Interpretation: Deep learning accurately distinguishes between [18F]FDG-PET-CT scans of lymphoma patients with and without hypermetabolic tumour sites. Deep learning might therefore be potentially useful to rule out the presence of metabolically active disease in such patients, or serve as a second reader or decision support tool. Funding: National Institutes of Health-National Cancer Institute Cancer Center Support Grant.

Clinical evaluation of deep learning‐enhanced lymphoma pet imaging with accelerated acquisition

Deep Learning Radiomics for Focal Liver Lesions Diagnosis on Long-Range Contrast-Enhanced Ultrasound and Clinical Factors

Low 18F-Fluorodeoxyglucose Dose Positron Emission Tomography Assisted by a Deep-Learning Image-Denoising Technique in Patients with Lymphoma.

Clinical performance of deep learning-enhanced ultrafast whole-body scintigraphy in patients with suspected malignancy

A hybrid few-shot multiple-instance learning model predicting the aggressiveness of lymphoma in PET/CT images

A 18F-FDG PET/CT-based Deep Learning-Radiomics-clinical Model for Prediction of Cervical Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma

Deep learning for [18F]fluorodeoxyglucose-PET-CT classification in patients with lymphoma: a dual-centre retrospective analysis

Prognosis Prediction of Diffuse Large B-Cell Lymphoma in 18F-FDG PET Images Based on Multi-Deep-Learning Models

Deep learning-based image analysis predicts PD-L1 status from 18F-FDG PET/CT images in non-small-cell lung cancer

Prognosis Prediction of Diffuse Large B-cell Lymphoma in $^{18}$F-FDG PET Images Based on Multi-Deep-Learning Models

Comprehensive framework for evaluation of deep neural networks in detection and quantification of lymphoma from PET/CT images: clinical insights, pitfalls, and observer agreement analyses

Multimodal Deep Learning Model on Interim 18F-FDG PET/CT for Predicting Primary Treatment Failure of Diffuse Large B-cell Lymphoma

Computer‐aided diagnostic models to classify lymph node metastasis and lymphoma involvement in enlarged cervical lymph nodes using PET/CT

Deep learning enhanced ultra-fast SPECT/CT bone scan in patients with suspected malignancy: quantitative assessment and clinical performance

Non-invasively Discriminating the Pathological Subtypes of Non-small Cell Lung Cancer with Pretreatment 18 F-FDG PET/CT Using Deep Learning

Deep learning system for lymph node quantification and metastatic cancer identification from whole-slide pathology images

Multimodal deep learning model on interim [18F]FDG PET/CT for predicting primary treatment failure in diffuse large B-cell lymphoma

Diffuse Large B-cell Lymphoma Segmentation in PET-CT Images Via Hybrid Learning for Feature Fusion

Deep learning-assisted ultra-fast/low-dose whole-body PET/CT imaging

Evaluation of 18F-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision

Radt-12. Deriving Imaging Biomarkers For Primary Central Nervous System Lymphoma Using Deep Learning